Lipid profile in normal weight migraineurs - evidence for cardiovascular risk

AbstractBackground:Excess weight, unhealthy lifestyle habits and their sequelae have become a well-recognized public health problem in most countries. The objective of the study was to examine the relationship of adolescent overweight/obesity with behavioral habits and their association with blood pressure (BP) and lipid profile.Methods:Anthropometric parameters, lifestyle, BP and lipid profile of 736 adolescents were evaluated cross-sectionally. The classifications of normal weight, overweight and obese were based on BMI z-scores.Results:About 42.1% of adolescents were overweight/obese, 11.3% were smokers, 33.2% consumed alcohol and 34% reported low activity. Males began smoking earlier, consumed alcohol more often, exercised less and spent more screen time than females. Alcohol consumption was more prevalent among smokers and was associated with higher BP and dyslipidemia. Smokers exercised less intensely and had lower high density lipoprotein-cholesterol (HDL-C) than non-smokers. Obesity was a risk factor for higher BP and dyslipidemia. Longer screen time was associated with higher triglycerides, while intense physical activity with lower systolic BP.Conclusions:Obesity is related to an adverse lipid and BP profile during adolescence. Clustering of hazardous habits was observed, which is known to aggravate the cardiovascular risk.

Download Full-text

SUN-575 Levels of Nesfatin-1 in Adolescents, and Its Association with Body Mass Index and Risk of Cardiovascular Disease

Journal of the Endocrine Society ◽

10.1210/jendso/bvaa046.673 ◽

2020 ◽

Vol 4 (Supplement_1) ◽

Author(s):

Karla Paola Gutierrez ◽

Carlos Kornhauser ◽

Armando Gómez ◽

Claudia Luevano-Contreras ◽

Mary Fafutis-Morris ◽

...

Keyword(s):

Risk Factors ◽

Cardiovascular Disease ◽

Cardiovascular Risk ◽

Lipid Profile ◽

Cardiovascular Risk Factors ◽

Statistical Tests ◽

Normal Weight ◽

Control Group ◽

Cross Sectional ◽

Obese Adolescents

Abstract Nesfastin-1 is a recently discovered anorexigenic neuropeptide, which seems to follow the signaling pathway of melanocortin, and is involved in cardiovascular regulation (1). It is expressed in several tissues, including pancreatic islet cells, the central nervous system, In subcutaneous and visceral fat tissue, among others (2). There are few and controversial data that assess the levels of nesfatin-1 and its relationship with the cardiovascular disease. The aim of this study was to evaluate the serum levels of nesfatin-1 in adolescents with different metabolic status and BMI and its association with cardiovascular risk factors (glucose, lipid profile). Material and methods: This cross-sectional study included adolescents between 15 and 19 years old, classified in 3 groups according to BMI and HOMA-IR: adolescents with normal weight without metabolic alterations (n = 30), metabolically healthy obese (MHO) n = 30 and metabolically unhealthy obese adolescents (MUO) n = 42. Anthropometric measurements were performed, a fasting blood sample was taken to quantify glucose, lipid profile and creatinine. Insulin and nesfatin-1 concentrations were measured by ELISA. Statistical tests employed were Kruskal Wallis, Spearman correlation. Results: the group of adolescents MUO had higher levels of total-C (p<0.0002); triglycerides (p<0.00001) compared to the control and MHO; higher levels of nesfatin-1 (p=0.0002) and lower levels of HDL-C (p<0.002) compared to the control group. A positive correlation was between nesfatin-1 and BMI (p<0.001), triglycerides (p<0.027), and HOMA-IR (p<0.025) and negative correlation with HDL-C (p<0.026) Conclusion: Our results show that metabolically unhealthy obese adolescents have higher concentrations of nesfatin-1, showing an association with traditional cardiovascular risk factors, which could lead to the development of cardiovascular disease. Nothing to disclose GK, KC, GOA, LCC, FMM, GA, GSME Sources of research support: Grant University of Guanajuato (DAIP 302/2018) References: (1) Oh-I et al., Nature. 2006; 443:709–712. (2) Stengel A et al., Regulatory Peptides. 2010; 163:18–23

Download Full-text

M.441 Lipid profile and number of cardiovascular risk factors (CVRF) in the prevencat study

Atherosclerosis ◽

10.1016/s0021-9150(04)90440-6 ◽

2004 ◽

Vol 5 (1) ◽

pp. 102

Author(s):

L LLVAREZSALA

Keyword(s):

Risk Factors ◽

Cardiovascular Risk ◽

Lipid Profile ◽

Cardiovascular Risk Factors

Download Full-text

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study

BMC Infectious Diseases ◽

10.1186/s12879-021-06304-3 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Andrea Giacomelli ◽

Federico Conti ◽

Laura Pezzati ◽

Letizia Oreni ◽

Anna Lisa Ridolfo ◽

...

Keyword(s):

Body Weight ◽

Cardiovascular Risk ◽

Lipid Profile ◽

Total Cholesterol ◽

Risk Score ◽

Rank Test ◽

People Living With Hiv ◽

Cholesterol Levels ◽

Signed Rank Test ◽

Living With Hiv

Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch to three different single tablet regimens (STRs) [tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV), TAF/FTC/elvitegravir/cobi (TAF/FTC/EVG/cobi) and ABC/lamivudine/dolutegravir (ABC/3TC/DTG)] in a cohort of people living with HIV/AIDS (PLWH) under effective ART. Methods All PLWH aged above 18 years on antiretroviral treatment with an HIV-RNA < 50 cp/mL at the time of the switch to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG were retrospectively included in the analysis. Framingham risk score modification after 12 months from the switch such as lipid profile and body weight modification were assessed. The change from baseline to 12 months in mean cardiovascular risk and body weight in each of the STR’s group were assessed by means of Wilcoxon signed-rank test whereas a mixed regression model was used to assess variation in lipid levels. Results Five-hundred and sixty PLWH were switched to an STR regimen of whom 170 (30.4%) to TAF/FTC/EVG/cobi, 191 (34.1%) to TAF/FTC/RPV and 199 (35.5%) to ABC/3TC/DTG. No difference in the Framingham cardiovascular risk score was observed after 12 months from the switch in each of the STR’s groups. No significant overtime variation in mean total cholesterol levels from baseline to 12 months was observed for PLWH switched to ABC/3TC/DTG [200 (SD 38) mg/dl vs 201 (SD 35) mg/dl; p = 0.610] whereas a significant increment was observed in PLWH switched to TAF/FTC/EVG/cobi [192 (SD 34) mg/dl vs 208 (SD 40) mg/dl; p < 0.0001] and TAF/FTC/RPV [187 (SD 34) mg/dl vs 195 (SD 35) mg/dl; p = 0.027]. In addition, a significant variation in the mean body weight from baseline to 12 months was observed in PLWH switched to TAF/FTC/EVG/cobi [72.2 (SD 13.5) kilograms vs 74.6 (SD 14.3) kilograms; p < 0.0001] and TAF/FTC/RPV [73.4 (SD 11.6) kilograms vs 75.6 (SD 11.8) kilograms; p < 0.0001] whereas no difference was observed in those switched to ABC/3TC/DTG [71.5 (SD 12.8) kilograms vs 72.1 (SD 12.6) kilograms; p = 0.478]. Conclusion No difference in the cardiovascular risk after 1 year from the switch to these STRs were observed. PLWH switched to TAF/FTC/EVG/cobi and TAF/FTC/RPV showed an increase in total cholesterol levels and body weight 12 months after the switch.

Download Full-text

POS-531 LIPID PROFILE AND CARDIOVASCULAR RISK IN CHRONIC HEMODIALYSIS PATIENTS

Kidney International Reports ◽

10.1016/j.ekir.2021.03.559 ◽

2021 ◽

Vol 6 (4) ◽

pp. S231

Author(s):

I. Nasri ◽

M. Khadhar ◽

S. Bouassida ◽

R. Lazzez ◽

S. Agrebi ◽

...

Keyword(s):

Cardiovascular Risk ◽

Lipid Profile ◽

Hemodialysis Patients ◽

Chronic Hemodialysis

Download Full-text

Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study

Annals of Medicine ◽

10.3109/07853890.2014.966752 ◽

2014 ◽

Vol 47 (1) ◽

pp. 40-46 ◽

Cited By ~ 21

Author(s):

Emmi Suomela ◽

Mervi Oikonen ◽

Johanna Virtanen ◽

Riitta Parkkola ◽

Eero Jokinen ◽

...

Keyword(s):

Young Adults ◽

Cardiovascular Risk ◽

Fatty Liver ◽

Normal Weight ◽

Young Finns Study

Download Full-text

AB0830 LIPID PROFILE IN PSORIATIC ARTHRITIS. FREQUENCY AND ASSOCIATION WITH DISEASE ACTIVITY.

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.2185 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1719.1-1720

Author(s):

V. Savio ◽

Y. Tissera ◽

M. I. Quaglia ◽

J. A. Albiero ◽

C. G. Alonso ◽

...

Keyword(s):

Cardiovascular Risk ◽

Psoriatic Arthritis ◽

Disease Activity ◽

Lipid Profile ◽

Activity Index ◽

Laboratory Data ◽

Disease Index ◽

Interleukin 12 ◽

Joint Involvement ◽

Apo B

Background:Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with higher risk of cardiovascular events and metabolic syndrome. The inflammation not only accelerates atherosclerosis, but also may influence cardiovascular (CV) risk factors such as lipid profile, blood pressure and insulin resistance. Lipid profile has previously been studied in PsA, however this association is still controversial.Objectives:To study the frequency of altered lipid profile in patients with PsA and its association with disease activity.Methods:We studied all the patients with diagnosis of PsA who consecutively attended to Rheumatology Unit at Cordoba Hospital from July 2018 to December 2019. PsA was diagnosed according CASPAR criteria. Clinical and laboratory data were collected. The activity of the disease was evaluated by PASI, MDA and DAPSA. Quantitative variables will be expressed in median and 1st and 3rd interquartile; qualitative variables expressed in frequency and percentage. Correlation analysis was calculated using Spearman’s rank correlation coefficient. P<0.05 was considered statistically significant.Results:42 PsA patients were included. Mean age was 56 years old (47.25-62.75) and 54.76% were female (n=23). 92.86% (n=39) of the patients had plaque Psoriasis and 87.8% (n=36) had peripheral joint involvement.Frequency of comorbidities in PsA are shown in Graphic 1. 31 (73.8%) of the patients were treated with topical therapy, 3 (7.14%) with phototherapy, 31 (73.8%) with Methotrexate and 17 (41.46%) with biologics and JAK inhibitor. Activity Disease Index and Lipid profile are shown in Table 1 and 2.There was not association between Apo B/Apo A coefficient with DAPSA (rho=0.013; p=0.940) and MDA (rho=-0.029; p=0.867).Conclusion:In spite of the presence of cardiovascular factors in the majority of PsA patients, lipid profile is not correlated with disease activity in this population.References:[1]Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study. J Intern Med 2011;270:147-57.[2]Mallbris, L., Ritchlin, C.T., Ståhle, M. “Metabolic disorders in patients with psoriasis and psoriatic arthritis.” Curr RheumatolRep.8(5): 355–363. 2006[3]Ng CY, Tzeng I-S, Liu S-H, Chang Y-C, Huang Y-H. Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (Ustekinumab). J Dermatol 2018; 45:309–313[4]Kaur S, Kingo K, Zilmer M. Psoriasis and cardiovascular risk – do promising new biomarkers have clinical impact? Mediators Inflamm 2017; 2017: 7279818[5]Gentile M, Peluso R, Di Minno MN, et al. Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis. ClinRheumatol 2016; 35: 2023-9.Graphic 1.Comorbidities in PsATable. 1.Activity Disease Index in PsAACTIVITY INDEXn=42DAPSA14.45 (9.72-23.92)DAPSA≤4 REMISSION3>4 y ≤14 low disease activity16>14 y ≤28 moderate disease activity17>28 high disease activity3cDAPSA14.00 (8.00-23.00)/41*MDA9 (25)/36PASI2.20 (0.20-6.80)/41**Expressed in median and interquartiles.Qualitative variables expressed in frequency and percentage.Table. 2.Lipid Profile in PsA patients.Cholesterol (mg/dl)194.5 (164.8-218.2)HDL (mg/dl)48.00 (37.00-57.00)LDL (mg/dl)114.5 (78.5-140.8)TG (mg/dl)139.50 (89.25-191.20)Expressed in median and interquartiles.Disclosure of Interests:None declared

Download Full-text

Serum Vitamin D Binding Protein Level Associated with Metabolic Cardiovascular Risk Factors in Women with the Polycystic Ovary Syndrome

Hormone and Metabolic Research ◽

10.1055/a-0759-7533 ◽

2018 ◽

Vol 51 (01) ◽

pp. 54-61 ◽

Cited By ~ 4

Author(s):

Justyna Kuliczkowska-Plaksej ◽

Renato Pasquali ◽

Andrzej Milewicz ◽

Felicja Lwow ◽

Diana Jedrzejuk ◽

...

Keyword(s):

Risk Factors ◽

Vitamin D ◽

Cardiovascular Risk ◽

Cardiovascular Risk Factors ◽

Polycystic Ovary ◽

Serum Insulin ◽

Normal Weight ◽

Control Group ◽

Vitamin D Binding Protein ◽

Ovary Syndrome

AbstractThe objective of the study was to measure the levels of 25-hydroxyvitamin D [25(OH)D] and vitamin D binding protein (VDBP) and assess their relationships with cardiovascular risk factors in women with the polycystic ovary syndrome (PCOS). A group of 267 women, aged 20–35 years (24.7 ± 4.9): 167 with PCOS and 100 healthy women were divided according to body mass index. Biochemical and hormonal parameters were measured. Free and bioavailable 25(OH)D were calculated using the mathematical equations. The percentage of body fat and visceral fat deposit were assessed by DXA. In the normal weight control group total, free, bioavailable 25(OH)D (p<0.001 for all) were significantly higher than in its overweight/obese counterpart, while VDBP levels were comparable. In PCOS women total 25(OH)D (p<0.001), and VDBP (p –0.006) were lower in the overweight/obese subgroups than in the normal weight ones. In both groups serum VDBP levels correlated negatively with serum insulin and positively with sex hormone binding globulin. In PCOS group, in contrast to control group, VDPB was negatively correlated with abdominal fat deposit, BMI, fasting glucose and positively with HDL. Despite lower total 25(OH)D in obese PCOS women, all women with PCOS (lean and obese) had comparable free and bioavailable 25(OH)D, which might be a result of concomitantly lowered serum VDBP levels in obese PCOS women. VDBP might play important role in the regulation of availability of active fractions of 25(OH)D in PCOS women. VDBP seems to be associated with cardiovascular risk factors such as BMI, waist circumference, visceral fat, and fasting serum insulin in women with PCOS.

Download Full-text